ClinicalTrials.gg
RecruitingNCT07676695AlAzharUUpdated Jun 30, 2026

Twin-Block and LIPUS for TMJ Outcomes in Skeletal Class II Patients

An interventional study of ultrasound in CLASS II DIVISION 1 MALOCCLUSION, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Open to participants aged 10 Months to 14 Months. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
10 Months to 14 Months
Sex
All
01

Study summary

Evaluation of the efficacy of early treatment of skeletal class II patients with twin-block in conjunction with low intensity pulsed ultrasound on temporomandibular joint region: a prospective clinical trial

Read the detailed description

In this study, twelve male and twelve female children with Class II malocclusion and retrognathic mandible were chosen from the outpatient clinics of the Department of Orthodontics at Al-Azhar University-Boys in Cairo. Their ages varied from nine to twelve.

The patients were split into two groups at random: the low intensity pulsed ultrasound group, which had an average age of 10.55 years, received daily direct application for the first ten days following the placing of the Twin Block appliance, then at least three times a week until mandibular advancement was achieved. LIPUS therapy was administered extra orally on the TMJ region bilaterally using a Sonopower DUO machine, India, LHC-2000.on the right and left sides at the TMJ. Sonication was accomplished by gently massaging the area of interest with 1.5 MHz frequency pulses with a 200-microsecond pulse width, for 20 minutes throughout each session, sonication was repeated at an average intensity of 30 mW/cm2. The control group, which received treatment with a twin block appliance without LIPUS, had an average age of 10.64 years. As part of the authorized orthodontic treatment plan for every patient in the research, the twin block was employed for nine months in both groups.

Prior to and during the Twin Block treatment phase, all patients had CBCT. in addition to the standard orthodontic records. Dentoskeletal measures and TMJ parameters were gathered, recorded, and statistically evaluated to compare changes in the variables within each group and between the two groups.

Version 23 of the SPSS software was used for statistical analysis. A significance criterion of p \< 0.05 was established.

02

Conditions studied

  • CLASS II DIVISION 1 MALOCCLUSION

Keywords

  • Class II div 1
  • Twin Block
  • CBCT
  • LIPUS
03

In context

Malocclusion, Angle Class II

124 studies on the registry are indexed under Malocclusion, Angle Class II; 19 are open to participants now.

This study's planned enrollment of 24 is below the median of 34 across 115 interventional studies indexed under Malocclusion, Angle Class II.

Browse Malocclusion, Angle Class II studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Months to 14 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Skeletal class II due to retrognathic mandible.
  • Angle's class II Molar relationship.
  • All patients involved in the study were in stages II and III based on the modified cervical vertebral maturation stages (CVMS) by Bacetti et al.5
  • Proclined upper incisors
  • Increased overjet > 5 mm.
  • Aligned lower arch or average inclination
  • Minimal crowding of lower arch.
  • No history of previous orthodontic treatment.

Exclusion criteria

Exclusion Criteria:

  • Skeletal class II due to prognathic maxilla.
  • Patient with gross facial asymmetry.
  • Previous orthodontic or orthopedic treatment.
  • Clinical signs and symptoms of any Temporomandibular joint disorders.
  • Increased anterior facial vertical dimension.
  • Poor oral hygiene.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • No intervention
    Control

    This group only receives functional treatment with twinblock without ultrasound

  • Experimental
    Lipus

    This group receives low intensity pulsed ultrasound inconjunction with functional treatment using twinblock

    Device: ultrasound

Interventions

  • Deviceultrasound

    low intensity pulsed ultrasound

06

What researchers measure

Primary outcomes

  1. linear measurements of condylar head

    Condylar head length (mm).

    Time frame: 9 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 86 non-industry interventional studies with no phase under Malocclusion, Angle Class II, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's planned 12 months is below that.

Counting every sponsor, half of 86 studies reached it within 15 months; a quarter within 11 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 30, 2026
StartActual
Jun 18, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07676695
Responsible party
Mohamed Hatem Refat Hablas (Principle investigator, Al-Azhar University) — Principal investigator
First posted
Jun 30, 2026
Start date
Jun 18, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Mohamed Ha Hablas
Contact
Mohamedhablas1995@gmail.com
01278988226
Hatem Re Abdelhamid
Contact
01002706800
Khaled Fa Abdallah
study director · Alazhar university in cairo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion